Stock MREO MEREO BIOPHARMA GROUP PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Mereo BioPharma Group plc

Equities

MREO

US5894921072

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 01/05/2024 am IST 		5-day change 1st Jan Change
3.05 USD +10.51% Intraday chart for Mereo BioPharma Group plc +9.71% +32.03%
30/04 European Equities Traded in the US as American Depositary Receipts Decline MT
26/04 European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 48.46 176.7 128.5 72.39 254.1 341 - -
Enterprise Value (EV) 1 64.53 171.2 50.96 27.14 254.1 212.5 198.9 341
P/E ratio - -1.09 x 51.6 x -10.3 x -45.4 x -325 x -65.8 x -38.1 x
Yield - - - - - - - -
Capitalization / Revenue - - 3.52 x - 25.4 x 12.4 x 27.3 x 326 x
EV / Revenue - - 1.4 x - 25.4 x 7.73 x 15.9 x 326 x
EV / EBITDA - -47,58,884 x - - - - - -
EV / FCF - - - - - -16.7 x -8.68 x -13.1 x
FCF Yield - - - - - -5.98% -11.5% -7.66%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 19,592 67,495 1,08,655 1,16,734 1,39,996 1,40,024 - -
Reference price 2 2.474 2.618 1.183 0.6201 1.815 2.435 2.435 2.435
Announcement Date 15/06/20 31/03/21 31/03/22 28/03/23 27/03/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - 36.46 - 10 27.5 12.5 1.045
EBITDA - -35.97 - - - - - -
EBIT 1 -39.52 -37.57 -20.94 -43.57 -28.42 -38.03 -43.02 -44.55
Operating Margin - - -57.42% - -284.16% -138.29% -344.2% -4,263.35%
Earnings before Tax (EBT) 1 -41.12 -166.4 14.24 -36.09 -30 -29.48 -33.17 -44.55
Net income 1 -34.84 -163.6 12.72 -34.2 -29.47 -8.265 -28.71 -44.55
Net margin - - 34.9% - -294.66% -30.06% -229.7% -4,263.35%
EPS 2 - -2.410 0.0229 -0.0600 -0.0400 -0.007500 -0.0370 -0.0640
Free Cash Flow 1 - - - - - -12.71 -22.92 -26.11
FCF margin - - - - - -46.21% -183.36% -2,498.33%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 15/06/20 31/03/21 31/03/22 28/03/23 27/03/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 - - - 36.46 - - - - - - 7.128 2.872 12.5 15 - -
EBITDA - - - - - - - - - - - - - - - -
EBIT -21.14 -16.69 -20.88 -0.204 -10.37 -10.37 -20.73 - -21.81 -21.76 -9.909 -18.51 -18.6 -19.43 - -
Operating Margin - - - -0.56% - - - - - - -139.02% -644.39% -148.8% -129.54% - -
Earnings before Tax (EBT) -22.44 -126.1 -40.35 10.9 - - 3.337 - -19.89 -16.2 -11.94 -18.06 -14.6 -14.88 -15 -15
Net income -18.62 -124.6 -39.01 12.09 - - 0.637 - -19.16 -15.04 -11.03 -18.44 -5.05 -3.24 -15 -15
Net margin - - - 33.15% - - - - - - -154.74% -641.92% -40.4% -21.6% - -
EPS - - -0.3500 0.0223 -0.1700 -0.1700 0.000620 - -0.0300 -0.0300 -0.0200 -0.0200 -0.008500 -0.003500 -0.0200 -0.0200
Dividend per Share - - - - - - - - - - - - - - - -
Announcement Date 15/06/20 29/09/20 31/03/21 02/11/21 31/03/22 31/03/22 31/03/22 02/11/22 02/11/22 28/03/23 07/09/23 27/03/24 - - - -
1GBP in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 16.1 - - - - - - -
Net Cash position 1 - 5.53 77.5 45.2 - 129 142 -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - - - -12.7 -22.9 -26.1
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 0.02 0.02 0.54 0.01 - 1 3 11
Capex / Sales - - 1.47% - - 3.64% 24% 1,052.63%
Announcement Date 15/06/20 31/03/21 31/03/22 28/03/23 27/03/24 - - -
1GBP in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Mereo BioPharma Group plc

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.435 GBP
Average target price
4.977 GBP
Spread / Average Target
+104.39%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MEREO BIOPHARMA GROUP PLC Stock Mereo BioPharma Group plc
+32.03% 427M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.46% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 96.09B
ARGENX SE Stock argenx SE
+2.13% 22.28B
BIONTECH SE Stock BioNTech SE
-15.84% 21.4B
GENMAB A/S Stock Genmab A/S
-9.19% 18.14B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.65% 16.09B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.39% 13.83B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+31.35% 11.97B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MREO Stock
  4. Financials Mereo BioPharma Group plc